Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: PK and PKPD Results from a Phase 2 Challenge Study in Healthy Participants Infected with RSV

Friday, March 14, 2025 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: EDP-323, a novel oral L-protein inhibitor, has shown promising results in a Phase 2 challenge study involving healthy participants infected with RSV. This first-in-class treatment is designed for once-daily administration, potentially offering a new therapeutic option for RSV. The study's pharmacokinetic and pharmacodynamic results indicate its efficacy and safety profile.
Price reaction · baseline $6.83 (2025-03-13 close) · hit pre-market · 3 other ENTA headline(s) in the window, move may be shared
day 0 close · peak
-2.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • EDP-323 is a first-in-class oral L-protein inhibitor.
  • The drug shows promise for treating RSV in healthy participants.
  • Results from the Phase 2 challenge study are encouraging.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EDP-323?

EDP-323 is a first-in-class oral L-protein inhibitor aimed at treating RSV.

What were the results of the Phase 2 study?

The Phase 2 challenge study showed promising pharmacokinetic and pharmacodynamic results.

How often is EDP-323 administered?

EDP-323 is designed for once-daily administration.

Who participated in the Phase 2 challenge study?

The study involved healthy participants infected with RSV.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EDP-323 RSV Phase 2 study L-protein inhibitor
Last updated: Mar 14, 2025

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →